India’s new crown epidemic in the spread of faster variant of the virus strains under the influence of rapid deterioration, all over the government in addition to strengthen preventive measures, India’s medical regulatory agencies on the 12th approved the third vaccine Russian satellite V (Sputnik-V) vaccine for emergency use.
India in the past 24 hours more than 160,000 new cases, the cumulative cases so far exceeded 13.69 million cases, the number of deaths also reached 171,098 people. Prime Minister Narendra Modi last week ruled out the possibility of another nationwide blockade amid a rapidly worsening epidemic, but news that local authorities may impose another total blockade or city closure in Maharashtra, the province where the outbreak is most severe, was reported.
India’s Directorate General of Drug Control (DGDC) announced on December 12 that it had granted emergency access to the Russian-developed Satellite V vaccine after an expert committee gave the green light to the vaccine.
The Satellite V vaccine is also the third vaccine to be granted emergency access by India’s drug regulatory authorities, the first two being vaccines developed by British pharmaceutical companies AstraZeneca and Oxford University and manufactured by the Serum Institute of India ( Covishield vaccine, which has the same composition as the AZ vaccine, and COVAXIN, a locally developed vaccine manufactured by Bharat Biotech International in India.
Russia’s Satellite V vaccine has a claimed 91.6% efficacy rate, second only to the Modena and Pfizer vaccines in the world.
India expects the addition of this vaccine to alleviate the current surge in vaccination demand due to the worsening epidemic.
Recent Comments